News

The companies have signed a collaboration and technology licence agreement for the worldwide application of DelSiTech’s Silica Matrix drug delivery platform to a number of Bayer’s compounds in

Arrowhead will get $35m up front and will be eligible to receive up to $617m in milestone payments. Amgen will also invest $21.5m in Arrowhead common stock. royalties

Under the terms of the agreement, GSK will provide €35 million support over a four year period, and Oncodesign will use this funding to integrate the site and

ViraTherapeutics, a biopharmaceutical company specializing in the development of oncolytic virus therapies, has developed its novel technology with joint support from its lead investors EMBL Ventures and Boehringer

As of the tender offer expiration, 115,574,041 shares of Medivation common stock were validly tendered, representing approximately 69.1% of the shares outstanding and have been accepted for payment

Erenumab, which is being co-developed by Novartis and Amgen, targets and blocks the Calcitonin Gene-Related Peptide (CGRP) receptor, which is thought to have a key role in mediating

As previously announced, Redx scientists have identified novel bacterial topoisomerase inhibitors that work as antibiotics against drug resistant Gram-negative bacteria. In vivo testing has now confirmed that Redx

Under the terms of the agreement, an immediate upfront payment of US$7.0 million is due to the co-investment partners and an additional fee of up to US$2.0 million

The new Agreement builds on the strategic collaboration between the two companies announced in January 2015 and will see C4XD and Evotec work together to develop new small